What is Neurocrine Biosciences's lessor, operating lease, payment to be received, after year four?

Neurocrine Biosciences (NBIX) reported lessor, operating lease, payment to be received, after year four of $2.00M in Q1 2026.

Other

Lessor, Operating Lease, Payment to be Received, after Year Four

Neurocrine Biosciences Lessor, Operating Lease, Payment to be Received, after Year Four decreased by 62.3% to $2.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 63.0%, from $5.40M to $2.00M.

Analysis

StatementBalance Sheet Statement

SectionOther

First reportedQ3 2023

Last reportedQ1 2026May 5, 2026

Metric ID: other_lessor_operating_lease_payment_to_be_received_afte_2c8f1c

Historical Data

8 periods

	Q3 '23	Q1 '24	Q2 '24	Q3 '24	Q1 '25	Q2 '25	Q3 '25	Q1 '26
Value	$6.00M	$4.30M	$7.00M	$8.80M	$5.40M	$5.40M	$5.30M	$2.00M
QoQ Change	—	-28.3%	+62.8%	+25.7%	-38.6%	+0.0%	-1.9%	-62.3%
YoY Change	—	—	—	+46.7%	+25.6%	-22.9%	-39.8%	-63.0%

Range$2.00M – $8.80M

CAGR-46.6%

Avg YoY Growth-10.7%

Median YoY Growth-22.9%

Current Streak2 quarters decline

Frequently Asked Questions

What is Neurocrine Biosciences's lessor, operating lease, payment to be received, after year four?: Neurocrine Biosciences (NBIX) reported lessor, operating lease, payment to be received, after year four of $2.00M in Q1 2026.
How has Neurocrine Biosciences's lessor, operating lease, payment to be received, after year four changed year-over-year?: Neurocrine Biosciences's lessor, operating lease, payment to be received, after year four decreased by 63.0% year-over-year, from $5.40M to $2.00M.